These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30925534)

  • 21. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AIDS/HIV. Finding footprints among the trees.
    Klenerman P; McMichael A
    Science; 2007 Mar; 315(5818):1505-7. PubMed ID: 17363650
    [No Abstract]   [Full Text] [Related]  

  • 23. APOBEC3G Regulation of the Evolutionary Race Between Adaptive Immunity and Viral Immune Escape Is Deeply Imprinted in the HIV Genome.
    Borzooee F; Joris KD; Grant MD; Larijani M
    Front Immunol; 2018; 9():3032. PubMed ID: 30687306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential immune escape mutations under inferred selection pressure in HIV-1 strains circulating in Medellín, Colombia.
    Arcia D; Ochoa R; Hernández JC; Álvarez CM; Díaz FJ; Velilla PA; Acevedo-Sáenz L
    Infect Genet Evol; 2019 Apr; 69():267-278. PubMed ID: 30808498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes.
    De Groot AS; Levitz L; Ardito MT; Skowron G; Mayer KH; Buus S; Boyle CM; Martin WD
    Hum Vaccin Immunother; 2012 Jul; 8(7):987-1000. PubMed ID: 22777092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of peptide selection approaches for epitope-based vaccine design.
    Schubert B; Lund O; Nielsen M
    Tissue Antigens; 2013 Oct; 82(4):243-51. PubMed ID: 24461003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV vaccine development by computer assisted design: the GAIA vaccine.
    De Groot AS; Marcon L; Bishop EA; Rivera D; Kutzler M; Weiner DB; Martin W
    Vaccine; 2005 Mar; 23(17-18):2136-48. PubMed ID: 15755584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring T & B-cell epitopes and designing multi-epitope subunit vaccine targeting integration step of HIV-1 lifecycle using immunoinformatics approach.
    Abdulla F; Adhikari UK; Uddin MK
    Microb Pathog; 2019 Dec; 137():103791. PubMed ID: 31606417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV/AIDS. HLA leaves its footprints on HIV.
    McMichael A; Klenerman P
    Science; 2002 May; 296(5572):1410-1. PubMed ID: 12029119
    [No Abstract]   [Full Text] [Related]  

  • 30. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.
    MacDonald KS; Matukas L; Embree JE; Fowke K; Kimani J; Nagelkerke NJ; Oyugi J; Kiama P; Kaul R; Luscher MA; Rowland-Jones S; Ndinya-Achola J; Ngugi E; Bwayo JJ; Plummer FA
    Immunol Lett; 2001 Nov; 79(1-2):151-7. PubMed ID: 11595302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 adaptation to antigen processing results in population-level immune evasion and affects subtype diversification.
    Tenzer S; Crawford H; Pymm P; Gifford R; Sreenu VB; Weimershaus M; de Oliveira T; Burgevin A; Gerstoft J; Akkad N; Lunn D; Fugger L; Bell J; Schild H; van Endert P; Iversen AKN
    Cell Rep; 2014 Apr; 7(2):448-463. PubMed ID: 24726370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep sequence analysis of HIV adaptation following vertical transmission reveals the impact of immune pressure on the evolution of HIV.
    Currenti J; Chopra A; John M; Leary S; McKinnon E; Alves E; Pilkinton M; Smith R; Barnett L; McDonnell WJ; Lucas M; Noel F; Mallal S; Conrad JA; Kalams SA; Gaudieri S
    PLoS Pathog; 2019 Dec; 15(12):e1008177. PubMed ID: 31821379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccines: where we are and where we are going.
    Haynes BF
    Lancet; 1996 Oct; 348(9032):933-7. PubMed ID: 8843815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extensive host immune adaptation in a concentrated North American HIV epidemic.
    Brumme ZL; Kinloch NN; Sanche S; Wong A; Martin E; Cobarrubias KD; Sandstrom P; Levett PN; Harrigan PR; Joy JB
    AIDS; 2018 Sep; 32(14):1927-1938. PubMed ID: 30048246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advances in the Immunogenic Design of HIV-1 Vaccine].
    Zhang X; Wang T; Yu X
    Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.
    Shearer GM; Pinto LA; Clerici M
    Immunol Today; 1999 Feb; 20(2):66-71. PubMed ID: 10098324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crosscurrents in HIV-1 evolution.
    Blankson JN; Bailey JR; Siliciano RF
    Nat Immunol; 2006 Feb; 7(2):121-2. PubMed ID: 16424885
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic HIV Peptide Vaccine.
    Fomsgaard A
    Methods Mol Biol; 2015; 1348():351-7. PubMed ID: 26424286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic.
    Schellens IM; Navis M; van Deutekom HW; Boeser-Nunnink B; Berkhout B; Kootstra N; Miedema F; Keşmir C; Schuitemaker H; van Baarle D; Borghans JA
    AIDS; 2011 Sep; 25(14):1691-700. PubMed ID: 21681058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selection of HIV escape mutants by CTL and adaptation of HIV to HLA class I].
    Takiguchi M
    Uirusu; 2009 Dec; 59(2):145-53. PubMed ID: 20218323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.